The Lotus Valve, a second-generation transcatheter aortic valve implantation (TAVI) device, was successfully implanted in all of the first 60 patients in results from REPRISE II, which showed good device performance and low mortality at 30 days.

The U.S. District Court for the District of New Jersey approved an agreement under which Vascular Solutions Inc. will cease further manufacture, sales and distribution of its R-Band Radial Hemostasis Device, pending litigation of Terumo Medical's patent infringement claims.

Direct Flow Medical Inc. said it met its primary endpoint in the fully-enrolled, 100-patient DISCOVER CE mark trial by achieving 99 percent freedom from all-cause mortality at 30 days. Patients were treated with the Direct Flow Medical Transcatheter Aortic Valve System and demonstrated excellent results relative to overall patient hemodynamics, as well as the avoidance of post-procedural aortic regurgitation and adverse events. The DISCOVER Trial full 30-day outcomes were presented today by trial investigator Joachim Schofer, M.D., from the Medical Care Center, Hamburg, Germany.

Abbott announced CE mark in Europe for the Xience Xpedition 48 Everolimus Eluting Coronary Stent System, the first-of-its-kind treatment for very long blockages in the vessels that supply blood to the heart due to coronary artery disease (CAD). 

CardioKinetix Inc. announced results of a meta-analysis study of the catheter-based Parachute Ventricular Partitioning Device. Six-month clinical results from 91 U.S. and European patients with ischemic heart failure were presented.

mGuard stent, STEMI

InspireMD Inc. announced new six-month results from the MASTER trial demonstrating that the MGuard embolic protection stent (EPS) outperformed bare metal stents and drug-eluting stents in all-cause mortality in ST-segment elevation myocardial infarction (STEMI) patients.

Welch Allyn has released its new FlexiPort EcoCuff blood pressure cuff and EarlySense Vitals surveillance system. Both products enable improvements in patient safety and clinical decision-making to help reduce risk for facilities.

Although not designed for cardiovascular surgery, a new robotic surgical system being developed will likely add to the growing interest of using magnetic resonance imaging (MRI) as a replacement for X-ray angiographic interventional procedural guidance.

Neovasc Inc. reported positive animal data from its Tiara program for the transcatheter treatment of mitral valve disease. Data presented is on long-term implantation of the Tiara mitral replacement valve in an animal model of mitral regurgitation (MR). 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now